Drug-resistant typhoid fever is a severe form of typhoid caused by Salmonella Typhi that no longer responds to standard antibiotic treatments. This condition is increasingly alarming as it threatens public health, particularly in low-resource settings where effective treatment options are already limited. The emergence of extensively drug-resistant (XDR) strains poses the risk of untreatable infections, making this a global health crisis that requires urgent attention. The mechanism behind drug resistance involves bacterial mutation and the development of resistance through genetic changes, accelerated by the increased use of antibiotics. As these bacteria adapt, they spread internationally, primarily through travel and poor sanitation conditions. Recent studies have shown a significant rise in XDR strains, particularly in South Asia, with transmission events recorded in countries as diverse as the United States and Canada, highlighting the global nature of this issue. Understanding drug-resistant typhoid is crucial for enhancing public health strategies, improving diagnostic methods, and raising awareness about hygiene practices and responsible antibiotic use. Such measures can lead to timely identification and treatment, ultimately reducing transmission rates. For instance, the introduction of effective vaccines in high-burden areas has shown promise in mitigating the impact of typhoid fever and its resistant variants. However, a major limitation in combating drug-resistant typhoid is the inadequate healthcare access in low-income countries, which hampers effective management and treatment. Misdiagnosis and delayed treatment can further exacerbate the situation, leading to increased resistance and higher mortality rates associated with untreated infections. Thus, addressing these challenges is critical for controlling the spread of drug-resistant typhoid.